Bruker Corporation (BRKR)vsEdwards Lifesciences Corp (EW)
BRKR
Bruker Corporation
$61.58
+0.31%
HEALTHCARE · Cap: $9.35B
EW
Edwards Lifesciences Corp
$88.34
+0.09%
HEALTHCARE · Cap: $50.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 86% more annual revenue ($6.51B vs $3.50B). EW leads profitability with a 15.4% profit margin vs -2.0%. BRKR appears more attractively valued with a PEG of 1.52. EW earns a higher WallStSmart Score of 55/100 (C).
BRKR
Hold37
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.2%
Fair Value
$45.25
Current Price
$61.58
$16.33 discount
Margin of Safety
+68.8%
Fair Value
$254.09
Current Price
$88.34
$165.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
Areas to Watch
Expensive relative to growth rate
Distress zone — elevated risk
Weak financial health signals
ROE of -0.5% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : BRKR
BRKR has a balanced fundamental profile.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : BRKR
The primary concerns for BRKR are PEG Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 52.5x leaves little room for execution misses.
Key Dynamics to Monitor
BRKR profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
BRKR carries more volatility with a beta of 1.26 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 37/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bruker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?